essening Organ Dysfunction with VITamin C (LOVIT) - LOVIT

niversité de Sherbrooke0 个研究点目标入组 800 人开始时间: 2019年11月13日最近更新: 2020年2月1日

适应症

试验速览

暂无简介。

•In both countries:
•1) Patients = 18 years old;
•2) Admitted to the ICU with proven or suspected infection as the main diagnosis;
•3) Currently treated with a continuous intravenous infusion of vasopressors (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine);
•5) Patient (or his representant) who has signed an informed and written consent;
•6) Affiliation to a social security system or to an universal health coverage (Couverture Maladie Universelle, CMU);
•7) Patients under guardianship or curatorship will be included;
•8) Patients in case of simple emergency (legal definition) will be included.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 700
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 100

•1) > 24 hours of ICU admission;
•2) Known glucose-6-phosphate dehydrogenase (G6PD) deficiency;
•3) Pregnancy;
•4) Known allergy to vitamin C; or to one of the excipients in particular methyl parahydroxybenzoate (E218) or propyl (E216);
•5) Known kidney stones within the past 1 year;
•6) Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;
•7) Expected death or withdrawal of life-sustaining treatments within 48 hours;
•8) Previously enrolled in this study;
•9) Previously enrolled in a trial for which co-enrolment is not allowed (co-enrolment to be determined case by case).

发起方

niversité de Sherbrooke